Ethical, social and legal implications of pharmacogenomics: a critical review
- PMID: 12751484
- DOI: 10.1159/000064194
Ethical, social and legal implications of pharmacogenomics: a critical review
Abstract
Objective: My aim was to examine the ethical, social and legal implications of pharmacogenomics.
Methods: I performed a critical review of the literature. The primary focal point is the bioethical principle discussed. The second outcome measure is the perspective of the discussion.
Results: This review documents that the pharmacogenomics issues of concern are comparable to issues concerning other genetic developments in general. However, two main issues are particular to the case of pharmacogenomics. Firstly, this review reveals that society, industry, groups and individuals appreciate the prospect of pharmacogenomics very differently. Secondly, there is a lack of research into the post-marketing implications of pharmacogenomics.
Conclusion: An extensive focus on the ethical, social and legal implications of pharmacogenomics, in terms of both pre- as well as post-marketing issues, is essential. Also, a multidisciplinary approach which includes individual and group opinions in an upfront manner in the research and development process is essential. Otherwise, there is a substantial risk that the positive prospects of pharmacogenomics will not survive due to fear and a lack of acceptance and understanding on the part of the general public.
Similar articles
-
Ethical, social and legal issues in pharmacogenomics.Pharmacogenomics J. 2003;3(4):194-6. doi: 10.1038/sj.tpj.6500188. Pharmacogenomics J. 2003. PMID: 12931132 Review. No abstract available.
-
Pharmacogenomics: questions and concerns.Curr Med Res Opin. 2005 Jul;21(7):1041-7. doi: 10.1185/030079905X50633. Curr Med Res Opin. 2005. PMID: 16004671 Review.
-
[Ethics, politics, and rights in pharmacogenomics].Rev Derecho Genoma Hum. 2002 Jul-Dec;(17):31-55. Rev Derecho Genoma Hum. 2002. PMID: 12703107 Review. Spanish.
-
Pharmacogenomics, ethics, and public policy.Kennedy Inst Ethics J. 2008 Mar;18(1):35-56. doi: 10.1353/ken.0.0004. Kennedy Inst Ethics J. 2008. PMID: 18561577
-
[The origin of informed consent].Acta Otorhinolaryngol Ital. 2005 Oct;25(5):312-27. Acta Otorhinolaryngol Ital. 2005. PMID: 16602332 Italian.
Cited by
-
No cure, no pay.BMJ. 2005 May 28;330(7502):1262-4. doi: 10.1136/bmj.330.7502.1262. BMJ. 2005. PMID: 15920131 Free PMC article. Review.
-
Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.J Mol Med (Berl). 2004 Jan;82(1):21-30. doi: 10.1007/s00109-003-0496-x. Epub 2003 Nov 4. J Mol Med (Berl). 2004. PMID: 14598045 Review.
-
Pharmacogenetics and pharmacovigilance.Drug Saf. 2009;32(3):265-70. doi: 10.2165/00002018-200932030-00009. Drug Saf. 2009. PMID: 19338384 No abstract available.
-
Striking a balance in communicating pharmacogenetic test results: promoting comprehension and minimizing adverse psychological and behavioral response.Patient Educ Couns. 2014 Oct;97(1):10-5. doi: 10.1016/j.pec.2014.06.007. Epub 2014 Jun 21. Patient Educ Couns. 2014. PMID: 24985359 Free PMC article. Review.
-
Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report.J Med Ethics. 2005 Mar;31(3):144-8. doi: 10.1136/jme.2004.007229. J Med Ethics. 2005. PMID: 15738433 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical